Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase I Treatment Closed 18 and over Pharmaceutical / Industry CA186-004
NCT00351325

Trial Description

Summary

The purpose of this study is to assess the safety and tolerability of multiple escalating doses of BMS-663513 when given in combination with paclitaxel and carboplatin.

Eligibility Criteria

Inclusion Criteria:

Good activity level

Life expectancy of ≥ 6 months

Solid tumor malignancy for which paclitaxel and carboplatin are appropriate

Exclusion Criteria:

Major surgery within 4 weeks

Any concurrent cancer

History of autoimmune diseases

Symptomatic bowel obstruction

Continued use of steroids

Symptomatic brain metastases

Current nerve damage in fingers/toes

Positive for HIV, hepatitis B/C

White blood cells < 3,000

Hemoglobin < 9

Platelets < 100,000

ALT/AST and/or alkaline phosphatase >= 2.5 x ULN

Creatine > 1.5

Prior BMS-663513

Trial Contact Information

Trial Lead Organizations/Sponsors

Bristol-Myers Squibb Company - New York

Bristol-Myers Squibb

Study Director

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00351325
Information obtained from ClinicalTrials.gov on May 07, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.